Simple, column purification technique for the fully automated radiosynthesis of [ 18F]fluoroazomycinarabinoside ([ 18F]FAZA)

Applied Radiation and Isotopes

Volumn 68, Issue 10, 2010, Pages 1944-1949

  Nandy, S K ^a   Rajan, M G R ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

18F FAZA; Hypoxia; Single column purification

Indexed keywords

[ 18F]FAZA; CHEMICAL IMPURITIES; DECAY CORRECTION; FLUORINE-18; NITROIMIDAZOLES; NUCLEOPHILIC FLUORINATION; ONE POT; PRECURSOR MOLECULES; PROTECTING GROUP; PURIFICATION TECHNIQUES; RADIOCHEMICAL PURITY; RADIOCHEMICAL YIELD; RADIOSYNTHESIS; TOTAL SYNTHESIS; TWO-STEP SYNTHESIS;

FLUORINE; HYDROLYSIS;

PURIFICATION;

1 (2,3 DI O ACETYL 5 O TOSYL ALPHA DEXTRO ARABINOFURANOSYL) 2 NITROIMIDAZOLE; FLUORINE 18; FLUOROAZOMYCINARABINOSIDE F 18; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SODIUM HYDROXIDE; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; DRUG HYDROLYSIS; DRUG IMPURITY; DRUG PURIFICATION; DRUG PURITY; DRUG STERILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORINATION; PRIORITY JOURNAL; QUALITY CONTROL;

AUTOMATION; CHROMATOGRAPHY; FLUORINE RADIOISOTOPES; ISOTOPE LABELING; METHODS; NITROIMIDAZOLES; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS;

EID: 77955280080     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2010.04.011     Document Type: Article

References (15)

1. 18F]fluoro-2-deoxy-D-glucose involving base hydrolysis. Radiochemistry 2002, 44:366-372.
2. 18F-labelled tracers: biology meets technology. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1563-1565.
3. 18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 1986, 27:235-238.
4. 18F]fluoro-2-deoxy-D-glucose: an efficient automated system for the aminopolyether-supported nucleophilic fluorination. Appl. Radiat. Isot. 1990, 41:49.
5. Hodgkiss R. Use of 2-nitroimidazole as bioreductive markers for tumor hypoxia. Anti-Cancer Drug Des 1998, 13:687-702.
6. 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J. Label. Compd. Radiopharm. 1999, 42:3-16.
7. Kumar P., Wiebe L.I., Asikoglu M., Tandon M., McEwan A.J. Microwave-assisted (radio) halogenation of nitroimidazole-based hypoxia marker. Appl. Radiat. Isot. 2002, 57:697-703.
8. Kumar P., Emami S., McEwan A.J.B., Wiebe L.I. Development of an economical, single step synthesis of FAZA, a clinical hypoxia marker, and potential synthons to prepare its positional analogs. Lett. Drug Des. Discov 2009, 6:82-85.
9. 18F fluoroazomycin arabinoside. J. Nucl. Med. 2005, 46:106-113.
10. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin. Cancer Res. 2004, 10:2245-2252.
11. 18F]FAZA: reaction parameters and automation. Appl. Radiat. Isot. 2005, 62:897-901.
12. 18F-misonidazole PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemo radiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J. Clin. Oncol. 2006, 24:2098-2104.
13. 18FMISO): a comparative study of their selective uptake on hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol. 2003, 30:317-326.
14. Startford I., Workman P. Bioreductive drugs into the next millennium. Anti-Cancer Drug Des. 1998, 13:519-528.
15. Wiebe L.I. PET radiopharmaceuticals for metabolic imaging in oncology. Int. Congr. Ser 2004, 1264:53-76.